Contact Us | bluebird bio
bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype
Our Leadership Team | bluebird bio
bluebird bio Launches Gene Therapy for Severe Blood Disorder in Germany | North Carolina Biotechnology Center
blue-ex991_25.htm
Flight Of The Navigator: Bluebird bio's Andrew Obenshain :: In Vivo
Articles with bluebird bio
Gene Therapy Could See Revival With Bluebird Drugs at FDA Panel - Bloomberg
bluebird bio to Present at the 37th Annual J.P. Morgan Healthcare Conference | Business Wire
Our Leadership Team | bluebird bio
Working at bluebird bio | Glassdoor
Press Release
Roche's Spark Therapeutics, bluebird resolve suit on sickle cell disease 'Spark' campaign | Seeking Alpha
bluebird bio Office Photos | Glassdoor
bluebird bio Office Photos | Glassdoor
Our Leadership Team | bluebird bio
Bluebird Bio nabs its 2nd gene therapy approval: The $3M Skysona
With the pricing situation 'untenable' in Europe, bluebird will wind down its operations in the 'broken' market
Two positive AdCom votes for bluebird bio encouraging for gene therapies
SEC Filing - bluebird bio, Inc.
Gene therapy: talking smart solutions with Bluebird Bio - Pharma Technology Focus | Issue 74 | September 2018
bluebird bio Dedicates New Biomanufacturing Plant in Durham | North Carolina Biotechnology Center
